Dr. Sarah Chen

Chief Scientific Officer, AntibodyLLM

Dr. Sarah Chen is Chief Scientific Officer at AntibodyLLM, where she leads the company's AI-driven antibody design research and scientific strategy. She joined AntibodyLLM at its founding in 2020 and has been instrumental in developing the platform's large language model-based sequence design engine and its proprietary CHO cell expression system.

Her expertise spans computational protein engineering, structural biology, CHO cell biomanufacturing, and the application of machine learning to antibody discovery and optimization. She has directed multiple projects achieving industry-leading results, including antibody expression yields of 3.2 g/L and picomolar binding affinities for novel oncology targets.

Areas of Expertise

• AI / LLM applications in antibody and protein design
• Computational sequence-structure-function modeling
• CHO cell stable expression systems (CRISPR, UCOE)
• Bispecific antibody engineering
• Recombinant protein production and process development
• Antibody affinity maturation and humanization

Publications by Dr. Sarah Chen

• The Future of AI-Driven Antibody Design — March 2026
• CRISPR Site-Specific Integration for Stable CHO Cell Lines
• UCOE Technology: Eliminating Gene Silencing in Stable Cell Lines
• How AI Reduces Antibody Development Costs by 50%
• Bispecific Antibodies: Challenges and Advances — February 2026
• Why CHO Cells Remain the Gold Standard for Antibody Manufacturing